Reprogramming Metabolism and Immunity: Nanotechnology's Promise for Hepatocellular Carcinoma Precision Therapy

Area of Science:

• Oncology
• Nanotechnology
• Immunology

Background:

• Hepatocellular carcinoma (HCC) presents treatment challenges including therapy resistance and low response rates to immune checkpoint inhibitors (ICIs).
• A key issue is the interplay between metabolic reprogramming and immune suppression within the tumor microenvironment, compounded by tumor heterogeneity.

Purpose of the Study:

• To elucidate the relationship between metabolic reprogramming and immune suppression in HCC.
• To outline the design principles for nanoplatforms capable of simultaneously intervening in both metabolic and immune pathways for HCC treatment.

Main Methods:

• Review of existing literature on metabolic reprogramming in HCC.
• Analysis of nanotechnology's role in targeting metabolic pathways (glucose, fatty acid, amino acid).
• Examination of nanoplatform synergy with ICIs and local therapies to modify the tumor microenvironment.

Main Results:

• Nanotechnology enables precise targeting and regulation of metabolic pathways, crucial for addressing HCC.
• Synchronous intervention via nanoplatforms can reshape the immunosuppressive tumor microenvironment.
• A strategy matching metabolic subtypes with specific nanocarriers demonstrates significant clinical potential.

Conclusions:

• Nanotechnology offers a powerful tool to overcome HCC treatment bottlenecks by addressing the metabolic reprogramming-immune suppression cycle.
• Future advancements require optimizing nanocarrier performance, developing personalized strategies based on multi-omics data, and establishing standardized evaluation systems.
• The evolution towards precise adaptation in nanotechnology promises to significantly advance precision therapy for HCC.